Oncology, neurology, and fatty liver disease are among the areas where one can expect to see significant activity this year, according to forecasts from investment bank analysts.

Anticipated highlights for 2020 include potentially the first regulatory approval of a drug to treat the liver disease nonalcoholic steatohepatitis, or NASH; the launches of two new drugs for sickle cell disease; and late-stage data for a drug to treat amyotrophic lateral sclerosis, among others. Several company executives also shared their insights in a story published over the weekend.

In Canaccord Genuitys forecast, analyst Edward Nash highlighted the big expectations in the disease NASH, which is the most severe form of nonalcoholic fatty liver disease. New York-based Intercept Pharmaceuticals obeticholic acid will go before an FDA advisory committee in on April 22, 2020, on the back of successful Phase II and Phase III data, thus potentially becoming the first drug approved for the disease in the middle of the year. Galectin Therapeutics, Galmed Pharmaceuticals, Genfit and Madrigal Pharmaceuticals are also expected to have Phase III data.

Allogeneic off-the-shelf cell therapies are also expected to be in the news, according to Canaccord Genuity analyst John Newman. Allogene is expected to have Phase I data in its product candidates in non-Hodgkins lymphoma and multiple myeloma in the first half of this year and by the years end, respectively. Meanwhile, Precision BioSciences is expected to have data in lymphoma and acute lymphoblastic leukemia in the first quarter. Allogeneic CAR-Ts are made with donor T-cells rather than the patients own T cells, as is the case with autologous CAR-Ts like the FDA-approved ones made by Novartis and Gilead Sciences.

In benign hematology, Newman highlighted the expected launches of recently approved sickle cell disease therapies, namely Novartis Adakveo (crizanlizumab) and Global Blood Therapeutics Oxbryta (voxelotor).

Another Canaccord Genuity analyst, Arlinda Lee, highlighted bispecific antibodies that may produce data this year, including those from Xencor, Y-mAbs Therapeutics and Zymeworks. However, BTIG analyst Thomas Shrader and colleagues pointed to both cell therapies and complex antibodies which would include bispecifics as areas of intense competition, with the large number of product candidates going after diseases like diffuse large B-cell lymphoma and acute lymphoblastic leukemia looking a little overwhelming.

Neurology and Cambridge, Massachusetts-based Biogen, the biggest company in that space also figured prominently in the forecasts. Its plan is to file for Food and Drug Administration approval of its controversial back-from-the-dead Alzheimers disease therapy, aducanumab, based on reevaluated data from the Phase III trials of the drug indicating that the amyloid beta-targeting therapy might have some efficacy after all. Declaring The 800lb gorilla returns, BTIG gave the drug about a 50% chance of winning approval when the FDA takes a closer look at the data. Anticipated topline data from the Phase III trial of BIIB067 in ALS, expected in the middle of this year, also garnered close attention.

Canaccord Genuitys report highlighted several other upcoming neurology catalysts ranging from FDA submissions to Phase III data readouts are expected for small- and mid-cap neurology-focused companies, like Acadia Pharmaceuticals, BioXcel Therapeutics, Intra-Cellular Therapies and others.

Aside from events in specific disease states and therapeutic areas, BTIGs Shrader wrote that 2020 looks like a ripe year for mergers and acquisitions, with the high-profile deals of 2019 being a good sign for the biopharma sector. Stoke Therapeutics, Alector, Gritstone Oncology and Sutro Biopharma were named as potential acquisition targets.

Photo: AndreyPopov, Getty Images

View original post here:
Analysts weigh in on what to expect in biopharma this year - MedCity News

Article In Brief

A large US-based study of recurrence of intracerebral hemorrhage (ICH) found that black and Asian patients are at a higher risk of ICH recurrence than whites, and private insurance was associated with significant reduced risk.

Black and Asian patients have a higher risk of recurrent intracerebral hemorrhage (ICH) than do white patients, according to a new longitudinal analysis published online December 12, 2019, in Neurology.

The study was led by a multi-institutional team of researchers from the US and the UK, the largest such study of ICH recurrence in a diverse US-based population.

The study also found that patients with private insurance have a significantly reduced risk of recurrent hemorrhagic stroke compared with patients on Medicaid and Medicare.

The issue of recurrence in ICH is a relatively new thing within the last decade, sayd lead study author Kevin N. Sheth, MD, FAAN, professor of neurology and neurosurgery, associate chair for clinical research in the department of neurology, and division chief for neurocritical care and emergency neurology at Yale School of Medicine.

Hemorrhagic stroke has been the deadliest stroke subtype, but over the years that mortality has declined. Now there are more survivors, and these issues surrounding what happens when you survive becomes more important. One of those issues is, what do we know about the chances of having another one?

Multiple studies have investigated racial and ethnic disparities in ischemic stroke, as well as in first-ever ICH, which is the most devastating form of stroke, associated with severe disability in most survivors and a 40 percent case-fatality rate at one month. But only one previous study had assessed these disparities in recurrent ICH. It too found that black patients were at higher risk than whites, although it did not find the same increased risk in Asians and did identify an increased risk in Hispanics.

On a large scale, our findings affirm these previous results suggesting that minority populations really are at higher risk for recurrent ICH compared to white populations, Dr. Sheth said.

In the new analysis, Dr. Sheth and his colleagues used 2005-2011 administrative claims data from the Healthcare Cost and Utilization Project California State Inpatient Database, which allows the tracking of individuals' hospitalizations over time in a large, racially and ethnically diverse population. All adult patients with a first-time diagnosis of ICH who survived to discharge and were California residents (to reduce bias related to lack of follow-up data) were included, unless they presented with a concurrent trauma diagnosis.

In the study populationcomprising 31,355 patients with an ICH diagnosis who survived to discharge1.4 percent, or 1,330 patients, experienced a recurrent ICH over a median follow-up of 2.9 years.

Compared with those who did not experience recurrence, patients with recurrent ICH were more likely to be black (11 percent vs 9 percent) or Asian (17 percent vs 14 percent, p=0.004). They were also less likely to have private insurance (18 percent vs 23 percent, p=0.001). Even after a sensitivity analysis excluding admissions with a concurrent diagnosis of infection within 30 days, black patients (HR 1.26; 95% CI 1.04-1.53; p=0.017) and Asians (HR 1.28; 95% CI 1.09-1.51; p=0.003) remained at an increased risk compared to whites, and those with private insurance remained at a reduced risk compared to patients with Medicare (HR 0.74; 95% CI 0.63- 0.86; p<0.001).

The mechanisms underlying these racial/ethnic differences remain unclear but are likely mediated by socioeconomic factors that disproportionately impact minorities, the study authors wrote.

Socioeconomic status may influence access to healthcare, early detection of hypertension and compliance with antihypertensive medications, which in turn impact the risk of recurrent ICH. Prior studies have shown that racial and ethnic minorities are less likely to achieve recommended blood pressure goals. Further study of interventions to control blood pressure in ICH survivors at both the individual and population level is warranted.

The insurance-related findings are consistent with several previous studies that have reported worse health outcomes in stroke patients with Medicaid and Medicare compared to those with private insurance. But the authors noted that it's difficult to tease out the underlying contributing factors. ...[I]t remains unknown whether these disparities represent true differences in the quality of care between insurance providers or if they represent confounding by baseline socioeconomic and health differences between groups, they wrote.

We have known for some time that there are various racial and ethnic disparities, as well as regional variation worldwide, in the incidence of ICH, said Sebastian Koch, MD, professor of clinical neurology and chief of the stroke program at the University of Miami's Miller School of Medicine. The highest rates of ICH are actually seen in Japan and China, which strongly suggests, perhaps, that there is some underlying biological reason why certain stroke subtypes may occur more frequently in some populations than others. What's particularly interesting about this study is that I think this is the first time that ICH in an Asian-American population was compared to other US racial and ethnic groups.

This paper confirms a lot of other data that we have regarding stroke in minority populations, agreed Mitchell S. Elkind, MD, MS, FAAN, professor of neurology and epidemiology at Columbia University Vagelos College of Physicians and Surgeons in New York City and an attending neurologist on the Stroke Service at the NewYork-Presbyterian Hospital.

What's unique about it is that it addresses hemorrhage and recurrent stroke, both of which are less common, so we have less data about those [conditions]. It also perhaps indirectly addresses the mechanism by which those disparities occur, because it suggests that patients with private insurance have a lower rate of recurrence than those with public insurance.

But experts were cautious about placing too much emphasis on the results regarding insurance status. There are significant confounding factors on this question, said Matthew L. Flaherty, MD, a neurologist at the University of Cincinnati Neuroscience Institute, a member of the UC Stroke Team, and a professor of neurology at the UC College of Medicine.

Patients who had recurrent ICH were less sick than patients who did not, suggesting that some of the sicker group died after discharge and were thus not at risk of recurrent hemorrhage. The recurrence group had shorter hospital stays, were less likely to be intubated, less likely to have a DNR order, and more likely to be discharged home. That suggests to me that this is a different population, probably influenced by medical comorbidities, and goals of care for these patients that might well differ in patients with different types of insurance status. This study could not identify patients who died outside the hospital. It's also likely there are unidentified socio-economic factors that differ by insurance status. Administrative databases in general are subject to things like coding errors, which is a limitation.

Nonetheless, said Dr. Elkind, it is reasonable to suggest that neurologists should be aware of a potentially heightened risk of ICH recurrence in minority populations and those who may have less access to health care resources. The underlying problem is often access to health care, whether it is doctor's visits or medications, so one may want to be especially attentive to those patients who may not have such access.

This paper adds evidence that despite our best attempts to adjust for common risk factorsthings like age, blood pressure, smoking, diabetes, and so onthere is a component to stroke recurrence, including ICH, that may be based on the genetics behind race or ethnicity, said Lee Birnbaum, MD, interim director of stroke at UT Health San Antonio.

We can't change a person's genetics, but we can certainly focus on known risk factors for first-time and recurrent ICH, and the most significant risk factor across all races and ethnicities is hypertension. Blood pressure is not just a primary care issue: neurologists should always be involved in the treatment of hypertension for stroke prevention, particularly after an ICH.

He noted that some blood pressure medications can be more or less effective in different populations, so the selection of these medications can be race- or ethnicity-specific. We also know that the Asian population can have more intracranial atherosclerosis than other populations, and so that may be a group to target more aggressively with cholesterol-lowering medicines, he said. However, there is evidence that intense lowering of LDL and cholesterol may possibly increase the risk for recurrent ICH, so the verdict on just how aggressive to be about lowering cholesterol after an ICH is still out.

At the clinician and practice level, treatment and management must take into consideration each patient's social situation, said Salvador Cruz-Flores, MD, FAAN, a stroke neurologist who is professor and founding chair of the department of neurology at Texas Tech University Health Sciences Center at El Paso.

Consider the difficulties that this person may have to even get to your office and try to find ways to adapt and allow them access to care. We aren't in a position to give away medications, but sometimes we tend to use the expensive ones as opposed to cheaper ones that may have similar efficacy in controlling blood pressure. We need to have culturally appropriate plans to engage and educate different populations in the importance of adherence to treatment.

Two secondary prevention trials for ICH survivors will be launching in 2020. ASPIRE is a randomized, double-blinded, phase 3 clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH. SATURN, a multicenter prospective, randomized, open-label, and blinded end-point assessment (PROBE) trial, aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar ICH is the best strategy.

This is very exciting; there has never before been a secondary prevention trial in ICH in the United States, said Dr. Sheth. Now there are more survivors, and the nihilism in the field is being chipped away.

Given this environment, Dr. Cruz-Flores suggests that the AAN and other professional societies should push to identify societal-level interventions to help narrow the disparities in access and outcomes identified by the new paper and the larger body of evidence around stroke care. That's where we can do better and where we are probably failing, he says. For example, the AAN could develop evidence-based guidelines to manage stroke recurrence in underserved populations. There must be a way that we as a society can manage these recurring and disproportionate risks for stroke.

Dr. Sheth agrees. As we do for other diseases, and for cardiovascular health broadly, we must better understand the details about disparities and access to care in ICH. What are the real drivers and how do we attack them?

Dr. Sheth, the senior author, receives research grants from the NIH and the American Heart Association. Drs. Koch, Elkind, and Salvador-Cruz had no competing interests.

More here:
Black and Asian Patients Face Elevated Risk of Recurrent... : Neurology Today - LWW Journals

While a lot more people are shifting to plant-based diets so as to achieve positive health results, they might not be reaping the benefits to the fullest as it is found that not all plants can do good to you.

In a new study, researchers have found that all plants arent good especially for the undernourished or people who depend on a single plant diet.

They also cautioned that growing interest in wild edibles raises the risk for people in wealthy countries, too, especially as some plants may become more toxic with changing climate, according to the findings published in the journal Environmental Neurology.

The bottom line is that plants and fungi were not put here for our benefit - they need to defend themselves, said Peter Spencer, professor of neurology in the OHSU School of Medicine and an affiliated faculty member of the Oregon Institute of Occupational Health Sciences at OHSU.

In the study, researchers catalogued a quartet of plants that sicken or kill undernourished people around the globe. The adverse neurological effects of food dependency on plant components with toxic potential constitute a significant global health issue, explained researchers.

Those in the list of the researchers include the potential neurotoxic effects of fruit of the ackee tree, an evergreen native to West Africa and favorite of Jamaica; lychee fruit, a delicious tropical fruit from southern Asia now eaten worldwide; grasspea, a protein-rich legume eaten on the Indian continent and the Horn of Africa; and cassava, a plant whose roots and leaves are consumed in across sub-Sahara.

Researchers elucidate ways in which they can rapidly and fatally affect brain function or, in the case of cassava and grasspea, gradually induce crippling disease.

This depends on the amount of plant product consumed along with the poor health of the people eating it; and the relative availability of each of these plants due to poverty, hunger and, increasingly, climate change.

Many people in Africa rely on cassava as a primary food source because it grows well in arid soils. But when stressed by drought, the concentration of its chemical defences increase at the same time water to wash out the toxic factors is in short supply. Those dependent on cassava develop an irreversible struggle to walk.

Researchers focused decades of their research in the field and laboratory on grasspea, a tasty legume that also causes tremor, muscle weakness and even paralysis in those who depend upon it for sustenance.

Unfortunately, Palmer said, people may well become increasingly exposed to potentially toxic plants as the climate warms and the global population expands, especially in low-income countries.

This is very concerning, particularly because many people are going to need to rely on these crops in the future, she said.

Spencer believes the exposome - the food we eat, the air we breathe, the chemicals we are unwittingly exposed to - is every bit as important in determining human health and preventing disease.

Prevention of brain disease is our principal goal-seeking and understanding the chemical causes of disease and minimizing human exposure, Spencer said.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed. )

Follow more stories on Facebook and Twitter

Go here to read the rest:
Heres why not all plant-based diets are good for you - Hindustan Times

H.E. Humaid Al Qutami, Director General of DHA, attended the event last week Image Credit: Nadeem Rasheed, DHA

In a bid to provide international experts and specialists in the field of neurology with a platform to exchange experiences and knowledge, the World Congress of Neurology 2019 (WCN2019) took place in Dubai last week.

The event, in its 24th edition, was held under the patronage of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of the Dubai Executive Council and was inaugurated by His Highness Sheikh Ahmed bin Mohammed bin Rashid Al Maktoum, Chairman of the Mohammed bin Rashid Al Maktoum Knowledge Foundation.

The congress, which was organised by the World Neurology Association and took place from October 27 to 31, discussed worldwide advancement of neurology in both scientific and clinical aspects, under the slogan Accelerating the Pace of Change.

The conference aimed to disseminate research, promote collaborative work in various fields of neurology and develop ethical guidelines for professional practices, especially in the areas of Alzheimers disease, strokes, multiple sclerosis, peripheral nerve diseases and Parkinsons disease.

The event also featured active discussions and cutting edge lectures by the worlds top scientists and neurologists in all fields of neurology including clinical medicine, research and future plans in neurology.

The congress hosted 165 speakers and 265 lectures. It also included an accompanying exhibition featuring 45 exhibitors.

A total of 4,000 participants from 125 countries took part in the event, which is considered the biggest congress on neurology in the world.

Dubai won the bid to host the congress, which takes place every two years, after competing with Johannesburg in South Africa.

In his keynote speech, His Excellency Humaid Al Qutami, Director General of DHA, commented on hosting this prominent event, saying:

Without a doubt, organising this medical event in the UAE and in Dubai the home of international government summits and forums will mark a new shift in the field of neurology, one of the most important medical specialties.

First, we would like to point out that our country and government believes that the wellbeing and health of our people is of its highest priority.

Excerpt from:
Dubai hosts the 24th World Congress of Neurology - Gulf News

BRIDGEWATER, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go Wearable Insulin Delivery device, which uses its proprietary h-Patch technology, announced positive data from its preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion was presented today at the 24th World Congress of Neurology held in Dubai, UAE.

In the poster presentation titled Delivery of Apomorphine via Subcutaneous Infusion with the h-Patch Wearable Device, the data demonstrated that 400ul of a 25mg/ml Apo solution delivered with the h-Patch technology was rapidly absorbed and was detected in plasma within two hours of the start of infusion. Additionally, Apo was still detectable in plasma 24 hours after completion of h-Patch infusion, or 48 hours in total.

Given both the side effects of oral dosing of Levodopa as well as the lack of small form factor subcutaneous delivery devices to effectively deliver Apo, we believe there is a significant unmet need that our wearable h-Patch device can satisfy for the effective delivery of Apo, said John Timberlake, President and Chief Executive Officer of Valeritas.

Valeritas proprietary h-Patch device is a simple all-in-one, fully disposable, drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The Companys V-Go is the first FDA-approved product that utilizes its h-Patch technology. To date, more than 20 million V-Go insulin delivery devices have been sold in the United States.

Treatment of advanced Parkinsons disease (PD) remains challenging, with fluctuations in motor status often resulting in patients becoming severely handicapped. The magnitude and pattern of the motor response to a single dose of subcutaneously administered Apo are qualitatively comparable to that of oral levodopa; however, side effects of oral dosing (dizziness, nausea, vomiting, etc.) can be problematic.

Close to a dozen clinical studies have shown subcutaneous Apo infusions are successful in aborting off periods, reducing dyskinesias, and improving PD motor scores with the added benefit of sparing the patient the challenging side effects of oral Levodopa. However, bulky infusion pumps requiring delivery of relatively large volumes of therapeutics remain a barrier to the development of therapeutic products that are patient and caregiver friendly, which may represent an opportunity for Valeritas comparatively smaller h-Patch technology.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas flagship product, V-Go Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for adult patients requiring insulin that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available atwww.valeritas.com and our Twitter feed @Valeritas_US,www.twitter.com/Valeritas_US.

Forward-Looking Statements

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: the ability to raise the additional funding needed to continue to pursue Valeritas business and product development plans; Valeritas' expected cash burn rate and its ability to continue to increase new and total prescription growth; the expected benefits of the debt exchange on Valeritas cash runway and its anticipated operating costs following the debt exchange (the $2 million minimum debt covenant remains in place following the debt exchange, which will continue to limit Valeritas ability to finance its operations); the effects of both the new issuance of Series B Convertible Preferred Stock and the May 2019 reverse stock split on the trading price of Valeritas common stock, in both the short and long-term; the ability to continue to commercialize the V-Go Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions; the inherent uncertainties associated with developing new products or technologies; the potential commercial use of the h-Patch technology for subcutaneous delivery of GLP-1, Apo or CBD is dependent on Valeritas ability to identify one or more potential collaboration partners and enter into mutually agreeable collaboration agreements (neither the delivery of GLP-1, Apo or CBD by h-Patch is currently cleared for use by the FDA); our statements that (i) subcutaneous Apo infusions appears to offer qualitatively comparable benefits to that of oral levodopa and (ii) based on initial studies, subcutaneous infusion of CBD appears to offer several distinct advantages over oral dosing of CBD, and other potential benefits of the h-Patch technology to deliver GLP-1, Apo or CBD is based on third-party clinical studies not conducted by Valeritas; however, additional studies or research may be needed by our potential partners to demonstrate to the U.S. Food and Drug Administration (FDA) that delivery of GLP-1, Apo or CBD via the h-Patch technology will offer consistent results to the initial Valeritas study; and the FDA or other regulatory agencies may require Valeritas collaboration partners to demonstrate the safety or effectiveness of subcutaneous infusion of GLP-1, Apo or CBD through the h-Patch technology before any of those products can be commercialized, which can be a lengthy, and uncertain process, and the FDA may delay or require additional information to provide clearance for use with our RHI or our V-Go SIM product. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at http://www.sec.gov.

Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin Group646-924-1769ir@valeritas.com

Media Contact:Kevin KnightKnight Marketing Communications, Ltd.206-451-4823pr@valeritas.com

Read this article:
Valeritas Presents Positive h-Patch Apomorphine Study Data at the World Congress of Neurology (WCN 2019) - GlobeNewswire

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

An exciting second day in Dubai started at 7.00 am with a masterclass in Neuro-Opthalmology. It was attended by a packed audience presented with an interestingassortment of cases by Dr Gordon Plant and Dr Vivek Laal.

The Plenary lecture on Reading in the Brain: Mapping the massive impact of literacy on brain circuits" was delivered by Prof. Stanislas Dehaene.

Dr Adrian Owen delivered the second plenary lecture on The Gray Zone and Brain Death."

Professor Russel Foster delivered the Soriano award lecture on light, circadian rhythms and sleep, mechanisms to new therapeutics. The first part of this brilliant lecture considered the discovery and clinical importance of the third photoreceptor system of the eye. The second part of the talk went on to discuss the connection between photoreceptor signal light, clockwork and sleep. He went on to discuss the detailed molecular changes during the circadian rhythm.

Dr Tedros, Director-General, World Health Organisation,delivered a video message on the WHO and recent collaborative outcomes.

Professor Raad Shakir, Immediate past president, WFN delivered the important news on ICD-11 and its impact on the future of neurology.

Professor William Carroll, President WFN delivered a lecture on the global role of World Federation of Neurology. Professor Bo Norrving delivered the much-awaited news on the implications of the reclassification of stroke as a neurological disease.

The WFN- Young neurologists, trainees and medical students informal gathering was a great success. Professor Tissa Wijeratne moderated the discussion. There was active participation. WFN trustees and the high-level leadership was available for the discussion and future of this group looks promising.

The number of parallel sessions covering dementia, headache disorders, movement disorders, MS and demyelinating disorders, dementia, neurooncology, advocacy, stroke medicine were highly successful.

Read the rest here:
Highlights from Day Two of the World Congress of Neurology 2019 - WFN News

Report byProf. Tissa Wijeratne MD FRACP FRCP (Edin) FRCP (London) FAHA FAAN (USA)

The atmosphere has been electric at the World Trade Centre, Dubai over the past five days. The excitement and joy of being in Dubai at the World Congress, serious as well as non-serious discussions among colleagues young and old, east and west, hustle and bustle, the diversity changed the WTC to a totally different place.

It has all come to an end today. What a fabulous world congress of neurology it has been! It is with mixed emotions I write this daily report to the membership worldwide.

The day began with an hour-long teaching course on headache disorders by Associate Professor Richard Stark, Treasurer and Trustee of the World Federation of Neurology. Given the enormous success of our world brain day campaign, it was fitting to focus on headache disorders on the final day.

There are one billion migraine patients with significant disability and a lot of room for improvement. The World Federation Neurology will continue to work with its member organisations and International Headache Society with a view to reaching out to resource-limited countries in the world as a priority.

Professor Nicolelis delivered the first plenary on Brain-Machine interfaces from basic sciences to neurorehabilitation. The research raises the possibility that properties of a robot arm, or other neutrally controlled tools, can be assimilated by brain representations as these tools were extensions of the subjects own body.

Professor Walter Koroshetz delivered the second plenary lecture on the promises of brain initiative for those with neuro/mental/substance disorders with a lot of promise for the future.

The paper discussed the current research on how brain circuits process information to enable human behaviour. The recent advances in the field opened up extraordinary possibilities for understanding animal and human behaviour and a lot of potential translating to the bedside.

The much-awaited semifinals and finals of the Tournament of the Mind was a sheer joy to watch, participate (delegates could vote on their smartphones to test their own knowledge), and enjoy the battle for the supremacy for the mind and brain!Sri Lanka, Hong Kong, Malaysia and India fought hard to secure the top spot but after a very close battle, Hong Kong pulled through as the overall winner. 4 other countries competed in a tiebreak with Sri Lanka taking 2nd place runners up. Warm congratulations to all teams, in particular to Hong Kong and Sri Lanka.

The 24th World Congress of Neurology has been an immense success. Let us meet again in Rome. We look forward to seeing you all in Rome in 2021.

Safe travel home, everyone. Keep visiting our website and social media streams to keep in touch.

See original here:
Final day highlights from the World Congress of Neurology 2019 - WFN News

Altru's neurology team focuses on the prevention, diagnosis and treatment of disorders of the body's nervous systems. Our team is made up of board certified physicians, neurosurgeon and a nurse practitioner, along with support staff.

To contact Altru's Neurology Department, please call 701.780.2300.

Medical care may include:

You may need to see a neurologist if you have been examined by a primary care physician and told that your symptoms are neurological in nature. Your primary care physician will consult a neurologist and schedule an appointment for an exam and possible tests. Once your exam and tests are completed, the neurologist will work with you to determine the plan or care which may include medication or therapy services.

In some cases, you may be referred to our neurosurgeon, if surgery seems most beneficial.

A neurosurgeon is responsible for the correction of disorders of the body's nervous system through surgery.

Altru's experienced, board-certified neurosurgeons perform surgical procedures on delicate parts of the body, including the brain, spine and individual nerves.

Working closely with Altru's neurologists, our team provides the best care possible to individuals affected by nerve disorders and diseases.

For information, please call 701.780.6427.

Altru's Multiple Sclerosis (MS) Specialty Clinic includes a day scheduled with multiple appointments of various specialists and services individualized for each patient. In addition to seeing the neurologist and nurse practitioner, patients will often be scheduled with a physical therapist, occupational therapist, speech language pathologist and a social worker/case manager. They may also be scheduled to see other specialists such as a dietitian for nutrition therapy, and have appointments with a urologist, optometrist or other physician's. Each patient's schedule is tailored to their specific needs

Altru's Multiple Sclerosis Specialty Clinic offers many advantages for our patients all in one convenient location, Altru 1300 Columbia.

To learn more about Altru's Multiple Sclerosis Specialty Clinic, call 701.780.2315.

See the article here:
Neurology - Altru Health System - Grand Forks, ND

Subscribe today and receive up to 20% off your first year's subscription! Applies for Individuals only.

IMPACT FACTOR 2018: 1.473

Seminars in Neurology is a review journal on current trends in the evaluation, diagnosis, and treatment of neurological diseases. Areas of coverage include multiple sclerosis, central nervous system infections, muscular dystrophy, neuro-immunology, spinal disorders, strokes, epilepsy, motor neuron diseases, movement disorders, higher cortical function, neuro-genetics and neuro-ophthamology. Each issue is presented under the direction of an expert guest editor, and invited contributors focus on a single, high-interest clinical topic.

Up-to-the-minute coverage of the latest information in the field makes this journal an invaluable resource for neurologists and residents.

Manuscript Submission All manuscripts must be submitted exclusively via online submission at http://mc.manuscriptcentral.com/sin

2019 Topics Include:

Emergency NeurologyDementia

Abstracting and indexing:

Journal Citation Reports (JCR), Emerging Sources Citation Index (ESCI), Biological Abstracts, BIOSIS, Current Contents/Clinical Medicine, EMBASE, Excerpta Medica, Index Medicus, MEDLINE, Neuroscience Citation Index, Research Alert, Scopus, Scisearch, EBSCO, ProQuest

Individual Rates: Personal subscription orders can only be placed by individuals and must include the recipient's name and personal address. Must be for individual use only and paid for by personal funds of the individual. Only qualified professionals and students are eligible for individual subscriptions.

For institutional subscriptions, please contact Institutional Sales for pricing at:

Please read our complete Terms of Trade for journal subscription policies.

Journal subscribers will receive a separate invoice and confirmation for your subscription order with taxes broken down separately as applicable and appropriate for your region.

Read more here:
Neurology | Seminars in Neurology - thieme.com

The primary focus of the Adult Neuropsychology Postdoctoral Fellowship at University Hospitals Cleveland Medical Center is to provide advanced training and education in the competencies necessary for the specialized practice of clinical neuropsychology. At the completion of the program, fellows should be capable of independent patient care, research and teaching in a range of settings including academic medical centers, hospitals and private practice.

The program is housed within the Department of Neurology at UH Cleveland Medical Center. UH Cleveland Medical Center is a 1,032 bed, nonprofit medical center in the University Circle neighborhood of Cleveland, Ohio, and is one of the primary teaching hospitals of Case Western Reserve University School of Medicine. UH Cleveland Medical Center is the anchor hospital of the University Hospitals Health System, which includes an integrated network of 18 hospitals, more than 40 outpatient health centers, 4,700 medical providers and more than 26,000 employees. The Department of Neurology is included within the Neurological Institute of University Hospitals and comprises 55 faculty across nine sites. Neurology houses multiple Centers of Excellence including Brain Health and Memory; Epilepsy; Movement Disorders; Stroke and Cerebrovascular Disorders; Critical Care Neurology; Community Neurology; and others. The Department of Neurology supports a large residency training program (12 per year for a total of 48 residents) and fellowship programs in Adult Neuropsychology, Pediatric Neurology, Neuromuscular Medicine, Vascular Neurology, Epilepsy, Clinical Neurophysiology (EEG) and Neurologic Intensive Care. UH Cleveland Medical Center is a thriving academic center. It houses an active clinical trials unit in neurology and has been ranked among the top 20 programs in the country for National Institutes of Health funding several consecutive years.

UH Cleveland Medical Center is consistently recognized as one of the nation's best hospitals by U.S. News & World Report. In 2016 2017, UH Cleveland Medical Center was named among the countrys Top 50 in eight methodology-ranked specialties including neurology and neurosurgery. These results place UH Cleveland Medical Center in the top 1 percent of the nations 5,000 hospitals eligible for ranking every year. In addition to the exceptional care provided to patients, resident and fellowship training is included among the primary initiatives of University Hospitals, aligning with its mission: To Heal. To Teach. To Discover.

The primary site for training in the Adult Neuropsychology Postdoctoral Fellowship Program is the UH Cleveland Medical Center Department of Neurology. However, patients are also seen at several satellite clinics around the Greater Cleveland area. Many of the services that the Neuropsychology Program provides involve a multidisciplinary, team-based approach and include frequent interactions with other specialist providers, both informally and in formal case conference formats. Fellows will also have opportunities for multidisciplinary team participation in the areas of dementia/memory loss, deep brain stimulation, epilepsy, normal pressure hydrocephalus, sports-related concussion and mild traumatic brain injury, among others.

Offices for faculty and fellows are located on the campus of UH Cleveland Medical Center. Each fellow is provided with a personal work space and his or her own computer/laptop. Fellows also have access to the medical library and online journals through UH Cleveland Medical Center.

The client populations served by the Department of Neurology are quite diverse in age, socioeconomic status and cultural background. The fellow will develop experience with clinical populations that include all forms of dementia and memory loss; deep brain stimulation and movement disorders; epilepsy and epilepsy surgery; normal pressure hydrocephalus; attention deficit hyperactivity disorder; learning disabilities; concussion and mild traumatic brain injury; traumatic brain injury; cerebrovascular disease and stroke; multiple sclerosis; neuro-oncology; and other conditions/syndromes. The fellows primary responsibilities will be diagnostic interviewing, neuropsychological assessment, and report writing; however, a substantial portion of the fellows schedule is blocked for didactics and research activities.

Although fellows will gain experience with a wide range of neurological conditions and patient populations, the Adult Neuropsychology Postdoctoral Fellowship at UH Cleveland Medical Center has four primary clinical service emphases: behavioral neurology, concussion management, general neurology and pre-surgical evaluation.

The Brain Health and Memory Center services at UH Foley ElderHealth Center provides care for the older adult patient. As part of a multidisciplinary team that also includes neurologists, geriatricians, nurse practitioners, nurses and social workers, neuropsychology plays an essential role in providing comprehensive outpatient care for this patient population. Neuropsychology fellows will have the opportunity to participate in UH Foley ElderHealth Centers integrated patient care model and gain experience with diverse patient populations. Referral questions/differential diagnosis often includes, but is not limited to, mild cognitive impairment and mild neurocognitive disorder; Alzheimers disease (including early onset); frontotemporal dementia; vascular dementia; lewy body dementia; posterior cortical atrophy; primary progressive aphasia; rapidly progressing conditions such as prion disease; Parkinsons disease; Huntingtons disease; multiple sclerosis; traumatic brain injury; stroke; and other medical, psychiatric and substance use disorders. Fellows will participate in individual feedback sessions with patients and their families and may also participate in summary visits alongside the referring neurologist/geriatrician and social worker on a case-by-case basis.

Fellows will also have the opportunity to engage in clinical didactic training experiences with UHs nationally recognized expert behavioral neurologists, Brian Appleby, MD, and Alan Lerner, MD. Opportunities for education and involvement in clinical research programs will be available including projects to examine prion diseases such as Creutzfeldt-Jakob disease and young-onset dementias in collaboration with the National Prion Disease Pathology Surveillance Center at Case Western Reserve University School of Medicine. Opportunities for involvement in multiple ongoing clinical trials through UH Foley ElderHealth Center will also be provided. These clinical trials are to explore new treatments for neurodegenerative conditions as well as caregiver education, methods and resources. For additional information about our behavioral neurology services, visit the Brain Health and Memory Center website.

The UH Concussion Management Program is a neuropsychologist-led, multidisciplinary, collaborative effort that provides comprehensive concussion care in order to safely return both sports and non-sports patient populations back to sports, school and work. UH Sports Medicine covers a large population of athletes in Northeast Ohio at all levels of athleticism including numerous youth leagues, 47 high schools and seven colleges/universities. We are also affiliated with several professional organizations including the Cleveland Browns (National Football League). In 2014, UH became one of only two Level I trauma centers in the Cleveland area, providing opportunities to work with patients who have sustained a wide range of neurological injuries of varying severity, including head trauma. Neuropsychological evaluation is an integral part of the concussion management process, with referrals coming at all phases of recovery depending on patient needs and concussion protocols.

Neuropsychological fellows will gain invaluable experience with multidisciplinary concussion management teams, concussion at all levels of sport, diverse populations and multiple contexts of injury. Our neuropsychology faculty are nationally recognized experts in the field of sports neuropsychology and have been active in establishing sports concussion legislation in Ohio as well as providing education regionally and nationally on concussion-related topics. Opportunities for concussion research are also be available for fellows, with our neuropsychology faculty currently acting as PI on multiple research investigations on concussion-related topics such as evaluating the use of subthreshold exercise in post-concussion syndrome; evaluating the effectiveness of youth concussion testing; evaluating new and leading-edge technologies for the diagnosis and management of concussion; and more. For further information, visit the UH Concussion Management Program website.

The Neuropsychology Program at University Hospitals receives referrals for comprehensive evaluation primarily from Centers of Excellence within UH Neurological Institute. However, additional referrals are received from other UH institutes and from outside institutions. UH Neurological Institute comprises a team of nationally recognized experts delivering comprehensive, coordinated care for disorders of the brain and nervous system. Recognized by U.S. News & World Report as one of the finest neurology and neurosurgery programs in the country, UH Neurological Institute includes 14 Centers of Excellence that provide individualized treatment, innovative techniques and access to some of the most innovative research designed to advance the science of neurological medicine.

For the Neuropsychology Program, the most common referral questions include differential diagnosis of neurodegenerative disorders and documentation of deficits associated with neurological diseases including stroke, head injury, neuro-oncology diseases, neurodegenerative diseases and many others. Neuropsychology fellows have the opportunity to complete outpatient neuropsychological evaluations of patients with a wide variety of referral questions and neurological diagnoses as well as opportunities to participate in integrated treatment teams. For more information, visit UH Neurological Institutes website.

Neuropsychology is a fully integrated and critical component of the deep brain stimulation (DBS), epilepsy surgery and normal pressure hydrocephalus (NPH) programs at University Hospitals. Neuropsychological evaluation is required at a patients pre-surgical evaluation and as part of post-surgical outcome monitoring for each service. Neuropsychology fellows and faculty meet weekly or biweekly with our surgical treatment teams to review neurocognitive findings in conjunction with other sources of data including the neurological and neurosurgical exam, EEG and neuroimaging results, levodopa response testing, and others. The team collaboratively determines appropriate interventions and plans for patients, with fellows obtaining invaluable experience in working with multidisciplinary treatment teams, presenting neuropsychological data to providers in related fields and working with diverse neurological populations.

Each of these programs is nationally recognized and led by faculty who are renowned as leaders in their respective fields.

For additional information on the UH Parkinsons & Movement Disorders Center, including the DBS program, visit our website.

For more information about the UH Epilepsy Center, including the epilepsy surgery program, visit our website.

For further information on NPH and other related services, visit our Brain Health & Memory Center website.

Read the rest here:
Adult Neuropsychology Postdoctoral Fellowship | For ...

Is there a cure for Alzheimers disease?

Some Alzheimers disease medications and management strategies may temporarily improve symptoms, thereby helping people with Alzheimers gain greater independence and maintain a good quality of life. However, there is no cure for Alzheimers disease, and its important to seek supportive services as early as possible.

An athletes prior history of concussions is perhaps the biggest risk factor related to his or her risk for another concussion. Research shows that if someone has already suffered one concussion, they are one- to two-times more likely to suffer another. The more concussions they suffer, the more their risk goes up.

Studies also show that females are more likely than males to sustain concussions, and that they require more recovery time. This is most likely due to a number of anatomical and biomechanical differences between genders.

Lastly, a history of developmental disorders, psychiatric disorders, or headaches/migraines can play a part in concussion recovery time. Since new research on concussions is always coming out, its important that coaches, trainers, parents, and athletes themselves stay up-to-date on information related to prevention and treatment.

First, there is a strong correlation between changes to your vision and the brain. For instance, strokes, aneurysms, brain tumors and even a brain infection can cause visual problems.

With that said, your first stop should be to either check in with an eye doctor, or consult your family physician. Plenty of visual problems are related to the eye itself, such as cataracts, glaucoma or astigmatism. If, after an eye exam, everything checks out, or if the problem includes other issues such as dizziness or migraines, make an appointment with the neurology department right away.

Neurologists do not perform surgery, but can recommend surgical treatment and refer patients to the appropriate surgeon if necessary.

Read the original post:
Neurology | Vancouver Clinic

Sessions/Tracks

On behalf of the Organizing Committee it is our pleasure to invite you to Neurology conference entitled21stWorld Congress on Neurology and TherapeuticsduringMarch 15-17, 2018atLondon, UK

Neurology 2018has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Committee.

Live format of the conference will be Accredited withCMEandCPDCredits

Neurological disordersare diseases of the brain, spine and the nerves that connect them. There is ample evidence that pinpoints neurological disorders as one of the greatest threats to public health. There are more than 600 diseases of the nervous system, such as Alzheimer's disease,brain tumors, epilepsy,Parkinson's disease, and stroke as well as less familiar ones such as frontotemporal dementia and an estimated 6.8 million people die every year as a result of these disorders there by making it necessary to investigate the unresolvedNeurological Disorder.

Track on:Migraine and Neuropathic pain

Neuropathic pain(neuralgia) is a pain that comes from problems with signals from the nerves. It was mainly classified into peripheral neuropathic pain and central neuropathic pain which includesspinal cordinjuryand central disorders. Pain is a significant public health problem that costs society at least and560-and635 billion annually. Women were more likely to experiencepainin comparison to men. According to the recent survey, Chronic Pain affects 47% of USA Adults. The main intent of this session is to understand Complex regional pain syndrome (CRPS) that is associated with dysregulation ofCentral Nervous System(CNS) and Autonomic Nervous System (ANS). The current session on clinical neurology and pain focuses on: Neurological conditions affecting people and treatment of neurological or personality disorders.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy, Neuro Informatics, Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Aneurysm FoundationandBrain InjuryAssociation of America, Inc.,EpilepsyFoundation and Epilepsy Institute,Huntington's Disease Society of America and Hydrocephalus Association,International Dyslexia Association and International Essential Tremor Foundation,International Rett Syndrome Foundation and IntracranialHypertensionResearch Foundation.Children'sBrain DiseaseFoundation,Myelin Repair Foundation and Myositis Association.

Track on:Neurodegenerative Disorders and Stroke

Neurodegeneration or neuron death is the progressive loss of structure or function ofneuronswhich includes disorders like Alzheimers disease, Parkinsons disease etc. In the United States, near about 60,000 cases of Parkinsons disease are diagnosed per year. The 3rd leading cause of death after cancer and heart disease is Stroke, thereby focusing on the epidemiology ofstrokeand risk factors. The main classification of stroke is haemorrhage stroke and ischemic stroke. The areas highlighted for discussion in this session are: Motor neuron diseases and Ataxias,Alzheimers Disease, Mechanism and Diagnosis, Novel Insights and Therapeutics for Parkinsons disease and Amyotrophic lateral sclerosis. Further we will discuss more about the various diagnosis procedure,Imagingtechnique, and acute stroke management,

Associations on Neurology

Migraine Research Foundationand MitoAction,NBIA Disorders Association and Neurofibromatosis Network,Brain Injury Resource Center and Brain Trauma Foundation,Epilepsy Therapy Project and Exceptional Parent Magazine,Huntington's Disease Society of Americaand Hydrocephalus Association,Multiple Sclerosis Association of America Multiple Sclerosis Foundation,Multiple System Atrophy Coalition, The MUMS National Parent-to-Parent Network

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Neuropathy Associationand Nevus Outreach, Inc,Brain Injury Resource Center and Brain Trauma Foundation,Epilepsy Therapy Project and Exceptional Parent Magazine,Huntington's Disease Society of America Hydrocephalus Association,Multiple Sclerosis Association of Americaand Multiple Sclerosis Foundation,Multiple System Atrophy Coalition, Theand MUMS National Parent-to-Parent Network

Track 3:Neuropediatrics and Neurorehabilitation

Paediatricneurologyevaluates children with disorders of the central and peripheral nervous systems. A large proportion in US population suffers from autism, mental retardation, dyslexia, seizures and other developmental disabilities. Approximately 1,300 U.S children experience severe or fatalbraintrauma from child abuse.Epilepsyis the fourth commonneurological disorderin the US after migraine, stroke, and Alzheimers disease. So there is a need to take into account, the following diseases to dissertate: congenital hydrocephalus,Autism, Neonatal encephalopathy, Paediatrics tumour, Neurodevelopment disorder, Epilepsy and Child psychological disorders.

Neurorehabilitation is a complex medical process which aims to aid recovery from a nervous system injury. Rehabilitation is an access to reduce brain abscesses thereby increasing the Neural Repair. Neurological rehabilitation program is aimed to create awareness about the neural disorders and its diagnosis.Physiotherapyand remediation is a novel approach that remediates impairments and promotes mobility. Conference on Neurology and Therapeutics is an effort to address all areas towardsNeurorehabilitationand Neural Repair.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Aneurysm Foundation andBrain InjuryAssociation of America, Inc.,EpilepsyFoundation and Epilepsy Institute,Jain Foundation and John Douglas FrenchAlzheimer'sFoundation,Children'sBrain DiseaseFoundation,Myelin Repair Foundation and Myositis Association,Migraine Research Foundationand MitoAction,NBIA Disorders Association andNeurofibromatosisNetwork

Track 4:Neuroinfections and Neuroimmunology

Neuroimmunology is a field of neuroscience, combining immune system and thenervous system. The immune system administer defence against these organisms, inefficiency of the same results in Infections. The condition is much worse in developing countries; it has been a significant health problem in Australia. Some 350,000 to 500,000 patients suffer from multiple sclerosis (MS) in the United States .The conference onneurologyis a platform to put our heads together and thrash out the cause of Multiple sclerosis and auto immune neuropathies,Neuroimmunologicalinfectious disease, Neuromicrobial disorders and Neurological Lyme diseases, Neuroinflamation, Neuroimmuno genetics. This session also includes to group think the alteration inneuromodulationand psychiatric diseases and the recent Drug development in the field of Neuro immunology.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Muscular Dystrophy Association and Musella Foundation forBrain TumorResearch and Information,Myasthenia Gravis Foundation of America, Inc. and Myelin Project, Myotonic Dystrophy Foundationand Narcolepsy Network, Inc.,Neuropathy Association and Nevus Outreach, Inc,National Organization on Disability and NationalParkinsonFoundation, National Patient Travel Center and NationalRehabilitationInformation Center

Track 5:Alzheimers Disease and Dementia

The brain immediately confronts us with its great complexity.Alzheimer'swhich is a type of Dementia is: An Underlying Disease that causes problems with memory,behaviourand thinking. As estimated,5.3 million Americans of all ages haveAlzheimer's diseasein the recent survey. AD is the sixth leading cause of death in the United States and the fifth leading cause of death in Americans of age 65 and older. The etiological factors, other than older age includesgeneticsusceptibility. so it is important to exchange views on Causes and Prevention of Alzheimers, Alzheimers Disease Diagnosis and Symptoms, Alzheimers Disease Pathophysiology and Disease Mechanisms, Care Practice and Awareness. we are also going to analyse the Alzheimers Disease Imaging , Mechanisms for Treatment andTherapeuticTargets.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, GermanyAssociations on Neurology

Muscular Dystrophy Association and Musella Foundation forBrain TumorResearch and Information,Myasthenia Gravis Foundation of America, Inc and Myelin Project, Myotonic Dystrophy Foundation and Narcolepsy Network, Inc.,Neuropathy Association and Nevus Outreach, Inc,National Organization on Disability and NationalParkinsonFoundation, National Patient Travel Center and NationalRehabilitationInformation Center

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Muscular Dystrophy Association and Musella Foundation forBrain TumorResearch and Information,Myasthenia Gravis Foundation of America, Inc. and Myelin Project, Myotonic Dystrophy Foundation and Narcolepsy Network, Inc.,Neuropathy Association and Nevus Outreach, Inc,National Organization on Disability and NationalParkinsonFoundation,National Patient Travel Centerand NationalRehabilitationInformation Center

Track 6:Neuromuscular Disorders

Neuromuscular disorders is known to affect the nerves that control the voluntary muscles. One of the causes is thegeneticand immune system disorder. More than a million people in the United States are affected by some form ofneuromusculardisease, and about 40 percent of them are under age18.Diagnosis includes a multi-step process like muscle biopsy, NCV test, biochemical, genetic test etc. The goal of this session is to understand the origin of spine muscular atropies,Musculardystrophy, Lambert-Eaton syndrome and other neuromuscular junction disorder. Further there will be an interactive conversation on Spasticy, Hyper reflexia and its prevention. In addition a talk will be deliberated on Is it true that High dose ofantibioticsleads to neuromuscular junction mal function and the findings in the field of neuromuscular medicine.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Aneurysm Foundation andBrain InjuryAssociation of America, Inc.,EpilepsyFoundation and Epilepsy Institute,Jain Foundation and John Douglas FrenchAlzheimer'sFoundation,Children'sBrain DiseaseFoundation,Myelin Repair Foundation and Myositis Association,Migraine Research Foundationand Mito Action,NBIA Disorders Association andNeurofibromatosisNetwork

Track 7:Neuroimaging and Brain Engineering

What seems astonishing is that engineering techniques likebrainengineering, or Neural tissue engineering can be used to understand, repair, replace, enhance, or otherwise exploit the properties of neural systems and Neurocomputing is the study of brain function in terms of the information processing properties of the structures that make up the nervous system. current researches in the field of neuroengineering include: Neural imaging and neural networking,Biomoleculartherapies in neural regeneration,Neurorobotics, Biological neural networking, Neuro hydrodynamics and clinical treatment, Engineering strategies for repair, Computational clinical neuroscience, biological-neuronmodelling, Behaviors of networks and advanced therapies. People will also be enlightened on Advancement in brain computer interface and deep brain stimulation.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome FoundationandIntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy AllianceandIron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseases and Jacob's Cure, Inc,Caregiver Action NetorkandCarter Centers forBrain Researchin Holoprosencephaly,Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder,Charcot-Marie-Tooth AssociationandCharlie Foundation for Ketogenic Therapies,Chiariand Syringomyelia FoundationandChildhood BrainTumorFoundation

Track 8:Neurosurgery and Neural Circuits

While the topic sounds pretty small, but we needs more speciality and critical care in this discipline. An estimated 69,720 new cases of primarybrain tumorsare expected to be diagnosed in 2013, that includes both malignant (24,620) and non-malignant(45,110) brain tumors. Basing on the prevalence of diseases, the conference focuses on Post-surgical neuralgias, Brain tumour and metastatis, Oncologicalneurosurgery, Spine neurosurgery, Neuroanaesthesia and surgery and Vascular malfunctions and surgery . The neurons are organized into ensembles called Anatomical and functionalneuralcircuits. Current researches identify disorders that affect different components of that neural circuit and a set of neural circuits that are critically involved in a specific disorder. Highest incidence rate of primary intracranial tumor was in Europe and the lowest rate in Africa. So it is requisite to enhance our knowledge on Currentneurosurgerymethod.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiari and Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 9:Neuropharmacology

Increase in technology and our understanding of the nervous system has lead to the development ofdrugsand medicines in the two main branches i.e. molecular and behavioural beyond our imagination that has continued to rise with an increase in drug specificity and sensitivity. current topic to be discussed are New pharmacological approaches for treatment ofneuraldisorders, drug development in cell signalling and synaptic spasticity, and the latest advancement in neuropharmacologcaltherapyand drug development in this particular sector. The present conference also aims to educate the researchers on Neuroimmuno pharmacology and Interfearance of pharmacological agents in neural disorder mechanism.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiariand Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 11:Neurogenetics

Genes affect the wiring and workings of thebrain, which is the authority of all our rides. It is ultimately and solely the genes that give rise to a particular type of protein that may be beneficial or harmful that reflects the need of research in this particular field. 6000 and more emerginggenetic disordersaccount for a significant portion of human disease and conditions. Nearly 4 percent of the approximately 4 million babies born each year have a genetic disease or major birth defect. Around 15,000 Americans are diagnosed to haveHuntingtonsdisease (HD).Keeping the same in view the following sub tracks are designed to enlighten the thoughts related to Huntington's disease (HD) and related genetic disorder, Genetic engineering to overcome neurological problems, The genes as a link between the brain andneurologicaldiseases, Gene defect and diseases, studies on genome wide association and disease diagnostics, sequencing of gene as a tool in determining the abnormal gene loci, Mutation of gene and neuronal migration defect.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiariand Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 11:Autonomic and Central Nervous System

Autonomic disorders may result from other disorders that damage autonomicnervesor they may occur on their own. Progressive autonomic failure usually becomes apparent in the sixth decade of life. The Working of the central nervous system has proved to be more and more extensive and more and more fundamental as experiment has advanced in examining it. CNS disorder can be eithermyelopathyor encephalopathy.

Specified disorders to be discussed under this category are: Bipolar disorder, Migraine and Neuropathic pain syndromes, Accessory nerve disorder, Autonomic dysreflexia and neuropathy, CNS disorder and structural defects, Facial nerve paralysis andMeningitis.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome FoundationandIntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy AllianceandIron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc,Caregiver Action NetorkandCarter Centers forBrain Researchin Holoprosencephaly,Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder,Charcot-Marie-Tooth AssociationandCharlie Foundation for Ketogenic Therapies,Chiariand Syringomyelia FoundationandChildhood BrainTumorFoundation

Track 12:Clinical Neurology and Neuropsychiatry

It is admirable to discuss about clinical neuroscience as this focuses on the fundamental mechanisms of diseases and disorders of the brain and central nervous system and seeks to develop new ways of diagnosing such anarchy, leading to the development of novelmedication. As per the estimates by the World Health Organization, neural disorders affect over 1 billion people worldwide, constitute 12% of the burden of disease globally, and cause 14% of global annihilation.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

International Rett Syndrome Foundationand IntracranialHypertensionResearch Foundation, Intractable Childhood Epilepsy Allianceand Iron Disorders Institute, ISMRD-International Advocate For Glycoprotein Storage Diseasesand Jacob's Cure, Inc, Caregiver Action Netork and Carter Centers forBrain Researchin Holoprosencephaly, Cerebral Palsy Foundationand CHADD - Childrenand Adults with Attention-Deficit/Hyperactivity Disorder, Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic Therapies, Chiariand Syringomyelia Foundationand Childhood BrainTumorFoundation

Track 13:Neurotherapeutics, Diagnostics and Case Studies

Various neurology conferences are held all over the world like world congress ofneurology2015 Chile in order to enhance and empower the knowledge of neuroscience. The 5th International conference on neurology and therapeutics that will be held at Madrid in March 2017, addresses all areas pertinent to this endeavour concentrating on NovelTherapeuticsand Diagnostics at the cellular and molecular level. There is a profound increase in the diagnostics procedure and drug discovery in the field of Neurology.

In order to accelerate the discovery of novel diagnostic therapy, the gathering of researchers is encouraged in order to discuss on the themeStem cellsin neurological disorder and treatment, Nerve injury and repair, Sleep disorders and headache,Neurogenesis, and last but not the least new therapeutics evolved for neurological disorders

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

Brain Injury Resource Center and Brain Trauma Foundation,Epilepsy Therapy Project and Exceptional Parent Magazine,Huntington's Disease Society of Americaand Hydrocephalus Association,Multiple Sclerosis Association of Americaand Multiple Sclerosis Foundation,Multiple System Atrophy Coalition, Theand MUMS National Parent-to-Parent Network

Track 14:Neurological Nursing

Neurological Nursing is a very challenging nursing specialty dealing with assessment, nursing diagnosis, and management of many neurological disorders in which nurses provide patient care. A Neuroscience Nurse assists patients with brain andnervous systemdisorders which includes trauma,brain injuries, stroke,seizures, tumours, headaches, infections, and aneurysms, as well as a host of other neurological complexities.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Neurologist Meeting

21stWorld Congress on Neurologyand Therapeutics, March 15-17, 2018 London, UK,7thGlobal NeurologistsAnnual Meeting on NeurologyandNeuro Surgery, August 22-24, 2018 Vienna, Austria, 2ndInternationalConference on Epilepsyand Treatment, October 20-21, 2018 Rome, Italy,Neuro Informatics,Alicantae, Spain, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany, 9th InternationalSymposium onNeuroprotectionandNeurorepair2018,Germany, 12th Congress of theEuropean Association ofNeuro-Oncology, Germany

Associations on Neurology

View original post here:
Neurology Conferences | Neurologists Conferences ...

International Conference on Neurology and Brain Disorders 2017 Report:

Magnus Group takes a great pride in announcing the International Conference on Neurology and Brain Disorders (INBC 2017) which was held in Valencia, Spain, during 26-28 June, 2017.

Neurology Congress 2017 witnessed a combination of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new fangled issues related to the field of Neurology. The extremely illustrious conference hosted by Magnus Group was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing their countries around the world.

For INBC 2017 Final Program: Click Here

The conference aimed with a theme Advancements and Challenges in Neurosciences & Brain Disorders. The summit engrossed a vicinity of sensible discussions on subjects like Neurodegenerative disorders, Behavioural Neurology, Neuropsychiatry, Paediatric Neurology, Neurological Disorders and Stroke, Neuroimmunology and Neurological Infections, Epilepsy & Seizure Disorders. The three days event implanted a firm relation of upcoming strategies in the field of Neurology, Neurodegenerative Disorders and Neurological Disorders and Stroke with the scientific community. The conceptual and valid knowledge shared, will also raise organizational collaborations to develop scientific accelerations.

For INBC 2017 Gallery: Click Here

Organizing Committee INBC 2017:

Giuseppe Scalabrino, University of Milan, Italy

Harry W.M. Steinbusch, Maastricht University, The Netherlands

Pankaj Sharma, University of London, UK

Henry Bakunts, International Medical Centre STROKE, Republic of Armenia

Mira Rakacolli-Kapisyzi, President of Albanian Society of Neurology, Albania

Serhiy Forostyak, Charles University, Czech Republic

The Organizing Committee would like to thank the moderators Dr.Leonardo Pignataro, Columbia University-City University of New york-CSI, USA, Dr.Udai Pandey, University of Pittsburgh Medical Center, USA,Michael Ugrumov, Institute of Development Biology RAS, Russia for their offerings which resulted in smooth functioning of the conference.

The conference was boarded with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The best Part of the conference were the keynote forum by prominent scientists, Sergi Ferre, National Institute on Drug Abuse(NID, NIH), USA; Marisela Morales, National Institute on Drug Abuse(NID, NIH), USA; Giuseppe Scalabrino, University of Milan, Italy; Harry W.M. Steinbusch, Maastricht University, The Netherlands; Pankaj Sharma, University of London, UK; Mira Rakacolli-Kapisyzi, President of Albanian Society of Neurology, Albania; Henry Bakunts, International Medical Centre STROKE, Armenia; gave their profitable contributions in the form of highly enlightening presentations and made the conference a best notch one.

Recommended Conferences: Neurology Conferences 2018 | Neuroscience Conferences 2018 | Neurology Conferences | Neuroscience Conferences | Brain Conferences

Magnus Group is prerogative to thank the Organizing Committee Members, Keynote speakers, Chair and Co-chairs on engross the plenary sessions, workshops, and special sessions in an expanded manner to make this conference a privileged Summit.

INBC 2017 Speaker Line Up:

Day 1: Speakers

Michel Baudry, Western University of Health Sciences, USA

Miranda N. Reed, Auburn University, USA

Stephen Wren, University of Oxford, UK

KHIN MAUNG BO, Northern Lincolnshire and Goole NHS Foundation Trust, UK

Mahmoud Kiaei, University of Arkansas for Medical Sciences, United States

Michael Ugrumov, Institute of Developmental Biology RAS, Russian Federation

Kimiko Inoue, Toneyama National Hospital, Japan

Caroline Corbel, Institut de Recherche Dupuy de Lome (IRDL), France

Jong Wook Chang, Samsung Medical Center, Korea

Nicole Hess, University of New England, Australia

Udai Pandey, University of Pittsburgh Medical Center, USA

Gabriele Saretzki, Newcastle University, UK

Shinji Ohara, Matsumoto Medical Center, Japan

Cristine Alves da Costa, Institut de Pharmacologie Molculaire et Cellulaire, France

Leonardo Pignataro, Columbia University-City University of New York-CSI, USA

Sabine Cordes, Lunenfeld-Tanenbaum Research Institute/Mt Sinai Hospital, Canada

Jeffrey Liddell, University of Melbourne, Australia

Niall Finnerty, Maynooth University, Ireland

Debashis Mukhopadhyay, Saha Institute of Nuclear Physics, India

Gilles Guillemin, Macquarie University, Australia

Abigail Takyi, University of Brighton, UK

Day 2: Speakers

Medvedev Svyatoslav, N.P.Bechtereva Institute of the Human Brain of the Russian Academy of Sciences, Russian Federation

Martin L. Pall, Washington State University, USA

Sergio Chieffi, Second University of Naples, Italy

Laura Calza, University of Bologna, Italy

Andrzej Pilc, Polish Academy of Sciences, Poland

Razvana Stanciu, Universite Libre de Bruxelles (ULB), Belgium

Kathryn Commons, Childrens Hospital Boston-Harvard Medical School, USA

Caroline Lucke, Medical Campus University of Oldenburg, Germany

Sabrina Wang, National Yang-Ming University, Taiwan

Marta Nieto, Spanish National Research Council, Spain

Viviane Rostirola Elsner, IPA Methodist University, Brazil

K.L. Leenders, University of Groningen, The Netherlands

Leah K. Light, Brainchild Institute, USA

Kenneth Gaines, Vanderbilt university Medical Center, USA

Bruno Gonzalez, Inserm - U1245 Team NeoVasc, France

Raquel Sofia Marques Neves, Amana Healthcare Medical and Rehabilitation Hospital, UAE

Marina Vladimirovna Zueva, Moscow Helmholtz Research Institute of Eye Diseases, Russia

Laehyun Kim, Korea Institute of Science and Technology, Korea

Prokopenko Semen, Krasnoyarsk State Medical University, Russian Federation

Luyang Tao, Soochow University, China

Anna Bezdeneznykh, Krasnoyarsk State Medical University, Russian Federation

M.R. Graham, Llantarnam Health Care, UK

Serhiy Forostyak, Charles University, Czech Republic

Gladstone C McDowell, Integrated Pain Solutions, USA

Saema Ansar, Lund University, Sweden

Barbara R. Cardoso, University of Sao Paulo, Brazil

Hassan Ravari, Mashhad university of medical sciences, Iran

Day 3: Speakers

Lars Hakan Thorell, Linkoping University, Sweden

Martin Egerth, Lufthansa Aviation Training GmbH, Germany

Munzberg Mathias, BG Klinik Ludwigshafen, Germany

Cecilia Montanez, Centro de Investigacion y de Estudios Avanzados del IPN, Mexico

Moataz Mohamed Talaat Mohamed Kamel El Semary, Cairo university, Egypt

Maria-Magdalena Georgescu, Louisiana State University, USA

Teruna J. Siahaan, The University of Kansas, USA

Toshiki Mizuno, Kyoto Prefectural University of Medicine, Japan

Katherine L Wisner, Northwestern University, USA

Meena Kumari, Kansas State University, USA

Magnus Gram, Lund University, Sweden

Joanna Czarzasta, University of Warmia and Mazury, Poland

Dennis J. Dlugos, University of Pennsylvania School of Medicine, USA

Lynda El-Hassar, Yale School of Medicine, USA

Hoi Ki Kate Lui, Tseung Kwan O Hospital, Hong Kong

Shuhei Yamaguchi, Shimane University, Japan

Victor Vvedensky, Kurchatov Inststute, Russian Federation

Michael Luedtke, Johnson & Johnson, USA

Fatimah Alqarni, King Abdullah bin Abdulaziz University hospital, Saudi Arabia

Bilgehan Atilgan ACAR, Sakarya University Faculty of Medicine, Turkey

Albekov Nurvadi, Chechen State University, Russia

Paul Chapple, Queen Mary University of London, UK

Turkan ACAR, Sakarya University Faculty of Medicine, Turkey

We once again thank all the participants for their wonderful involvement towards the event which helped us for successful execution of this event.

After the successful completion conference, we are exhilarated to announce our next upcoming 2ndEdition of International Conference on Neurology and Brain Disorders (INBC 2018) which is going to be held during June 04-06, 2018 in Rome, Italy.

Mark your calendars for the upcoming spectacular event; we are hoping to see you soon!

Link:
Neurology Conferences 2018 | Neurology Congress 2018 ...

SIOUX FALLS Avera Medical Group announces Neurology Associates, P.C., of Sioux Falls and its physicians will join Avera Medical Group, and the clinic will come under Avera ownership in June.

The physicians of Neurology Associates have been on the medical staff of Avera McKennan Hospital & University Health Center for a number of years, and have served the neurology needs of Avera patients with high quality care, said David Flicek, Chief Administrative Officer for Avera Medical Group. We are proud to welcome them as members of Avera Medical Group. The neurology clinic is located in Plaza 2 on the Avera McKennan campus. The practice also has a Headache Center located at 6709 S. Minnesota Ave.

The name of the practice will change to Avera Medical Group Neurology. The physicians in the practice include Carol Nelson, MD; William Rossing, MD; Todd Zimprich, MD; Lisa Viola, DO; Karen Garnaas, MD; Jeffrey Boyle, MD, PhD; and Warren O.V. Opheim, MD. All are board certified in neurology. Several have advanced subspecialty education in such areas as epilepsy, headache medicine, movement disorders, neuromuscular disease and sleep. They also have special interest in Parkinsons disease, multiple sclerosis, stroke and other conditions that are difficult to diagnose. Together, they comprise the largest neurology practice in South Dakota.

This group of neurologists has been instrumental in the high quality of care delivered through the Avera Brain & Spine Institute, Flicek said. This includes the Stroke Center at Avera McKennan, which is certified as a Primary Stroke Center by the Joint Commission and is nationally recognized for excellence, a specialized neurosciences unit at Avera McKennan, Balance and Dizziness Center, and Autonomic Testing Lab. Now having the neurologists as part of Avera will bring an added measure of comprehensiveness and cohesiveness to our overall neurosciences program, Flicek said.

My colleagues and I have enjoyed close collaboration with Avera over the years, and we have appreciated their support in the development of advanced neuroscience care. We closely identify with the Avera sense of health ministry and mission, and are excited to become part of Avera Medical Group and the wider Avera family, said William Rossing, MD, Neurologist who also serves as director of the Stroke Center at Avera McKennan.

Avera Medical Group Neurology is the largest neurology practice in South Dakota. The 35 employees of Neurology Associates will become employees of Avera. We are looking forward to positioning both Avera and Neurology Associates for the changes that are coming through health care reform, Flicek added.

Follow this link:
Avera Medical Group Welcomes Neurology Associates

ATHENS Neurologist Dr. Douglas A. Woo will join the OhioHealth OBleness Hospital medical staff on Wednesday.

Woo is a board-certified neurologist specializing in multiple sclerosis. Additionally, Woo treats the full range of neurology, including dizziness, stroke, seizure, dementia and head/neck pain. He also provides botulinum toxin injections and myofascial trigger point injections to treat selected variants of headaches and neck pain.

Woo received his undergraduate degree from Marquette University and his medical degree from the Medical College of Wisconsin, both in Milwaukee, Wisconsin. He also completed his internship and neurology residency at the Medical College of Wisconsin. He completed a fellowship at the University of Texas Southwestern Medical Center at Dallas focused on the treatment of multiple sclerosis. He is a member of the American Academy of Neurology.

ATHENS - Authorities in Athens County have identified a Meigs County man as the kayaker missing since Saturday ...

A power interruption originally scheduled for Monday has been canceled because of the efforts to restore power ...

PARKERSBURG The Ohio River Valley Water Sanitation Commission has elected Stuart F. Bruny of Logan, Ohio, as ...

PARKERSBURG A familiar face has returned to the Blennerhassett Hotel. Yancy Roush has been hired as the new ...

Read more:
Neurologist Dr. Douglas A. Woo joins O'Bleness Hospital staff - Parkersburg News

Neurology is the medical specialty which focuses on the diagnosis and treatment of diseases and disorders of the brain and nervous system. A physician who practices neurology is called a neurologist. A surgeon who operates on the brain is called a neurosurgeon, which is a surgical specialty rather than a medical specialty.

Neurologists treat stroke patients, as well as patients with traumatic brain injury, epilepsy, Alzheimer's disease, Parkinson's disease, movement disorders, neuromuscular disorders, multiple sclerosis, headaches, and hundreds of other neurological issues, some of which are acute, others of which may be ongoing, or chronic.

Neurology is a field that will have an increasing need for practitioners as an aging population will have more incidence of stroke, Alzheimer's disease, and Parkinson's disease.

A doctor who wishes to become a neurologistfirst attends medical school and graduates with a DO or MD medical degree. Then the doctor would complete a year as an intern in internal medicine and three years of residency in neurology.

Board certification is conducted by the American Board of Psychiatry and Neurology. They provide specialty exams in neurology and neurology with special qualification in child neurology. Subspecialty certifications are available in brain injury medicine, epilepsy, hospice and palliative medicine, neurodevelopmental disabilities, neuromuscular medicine, pain medicine, sleep medicine, and vascular neurology. Certification is dependent on a three-year cycle of maintenance of certification and examinations every 10 years.

Many neurologists work in private practice as part of a specialty group or multispecialty group. But they may also work for hospitals, the military, and managed care organizations.

A patient may be referred to a neurologist for any symptoms that point to the brain or nervous system.

These include seizures, confusion, changes in sensation, muscle and coordination problems, headaches, or after a blow to the head.

The chief diagnostic procedure in neurology is a very thorough history and physical examination. This is where the reflex hammer comes into play. A patient will get a thorough check of the function of all of the cranial nerves, reflexes, and coordination.

The neurologist may order a lumbar puncture to test spinal fluid if the symptoms warrant it. An EEG, CT, MRI, PET scan, or angiography may also be ordered and examined. Neurologists who specialize in sleep medicine may conduct sleep studies. Electromyogram and nerve conduction studies might be done when there is peripheralnervous system symptoms.

Neurological diagnoses can take time and elimination of many rare conditions and disorders. It is one reason that the residency for neurology is specific and three years long. Treatments for neurological diseases may be limited, so reaching a diagnosis does not immediately provide a healing path for the patient.

Neurologists may see a wide range of patients, from a young adult with a brain injury sustained from sports, a fall, or explosive device in a war zone, to an elderly patient showing signs of dementia, or a child with a seizure disorder.

Read the original post:
What Is Neurology and What Does a Neurologist Do?

EXTON, Pa., March 10, 2020 /PRNewswire/ -- In the last year, the US multiple sclerosis (MS) market saw the introduction of three new disease-modifying therapies (DMTs) for the treatment of relapsing forms of MS (RMS). Fielded between January 21 and February 12, data from 100 neurologists surveyed for the Q1 wave of the ongoing quarterly report series, included in Spherix's RealTime Dynamix: Multiple Sclerosis (US)service, provide insight into the current patterns underlying each of these individual launches.

In March 2019, alongside the approvals of Mayzent and Mavenclad, the FDA revisedthe RMS label for previously approved DMTs to explicitly include clinically isolated syndrome (CIS)1 and active secondary progressive MS (SPMS). The expanded label has had an immediate impact, with neurologists significantly more likely to agree that DMTs approved for RMS would be effective in active SPMS compared to a year ago. While historically among the most commonly switched-to DMTs for active SPMS, this change may also have provided Genentech's Ocrevus with fuel for further uptake, as chronic/advanced disease is now seen a less of a barrier to treat active SPMS patients.

Competitiveness of Novartis' Mayzent with Genentech's Ocrevus for active SPMS appears to be slipping, with fewer active SPMS patients identified as appropriate Mayzent candidates and neurologists more likely to believe that Ocrevus outperforms Mayzent on efficacy in active SPMS compared to nine months ago. Perhaps as a result, Novartis appears to be focusing more on the broad RMS indication and encouraging use in place of Novartis' own Gilenya, the first S1P receptor modulator launched back in 2010.

The reported prescriber base for EMD Serono's Mavenclad has remained flat over the past three months. Neurologists who have yet to prescribe are less likely to believe in Mavenclad's efficacy in reducing the risk of disability progression, favorable risk/benefit profile, and status as a preferred active SPMS option compared to prescribers. In addition, even these early adopters appear less enthusiastic about the breadth of their future Mavenclad uptake, with substantial declines in the estimated percentage of RRMS and active SPMS patients who would be appropriate candidates for the brand over the past three months. EMD Serono will need to prioritize discussions related to appropriate post-Mavenclad maintenance therapy and long-term safety data, while continuing to promote the therapy's unique dosing profile, to compete successfully with Ocrevus.

Trial of Biogen's Vumerity, a next-generation fumarate agent with an improved gastrointestinal tolerability profile compared to Biogen's own Tecfidera, has been swift within the first month of availability with most uptake occurring among RRMS patients switching from Tecfidera. However, remaining nonprescribers may be a tougher sell as they are less likely to believe in the superior tolerability profile or to agree that Vumerity will replace Tecfidera in treatment-nave patients who are candidates for a fumarate agent. As such, almost half plan to wait at least six months before initiating a patient on Vumerity. Reflecting a change from Spherix's Q4 2019 pre-launch assessment, neurologists now estimate a flat fumarate class share over the next six months, highlighting the strong competition within the fumarate class. Patient outreach and education may be a vastly underutilized opportunity for Vumerity, as the majority of patient requests resulted in a prescription and yet only 12% of neurologists have received a Vumerity request within the past three months.

Even with these recent launches of new oral options, the neurologist-reported oral DMT class share has remained flat over the past year, due to stagnant shares of established oral DMTs Gilenya, Tecfidera, and Genzyme's Aubagio. With Gilenya and Tecfidera under pressure from their respective next-generation molecules, neurologists anticipate significant share declines for these brands over the next six months. While Aubagio appears to be immune for now, the Genzyme brand may feel increasing heat with the much-anticipated June 2020 regulatory decisionfor Novartis' ofatumumab, as the subcutaneous anti-CD20 monoclonal antibody was shown to be superior to Aubagio for the treatment of RMS in the Phase III ASCLEPIOS clinical trials.

Along with ofatumumab, two more S1P receptor modulators may be entering the US market within the next nine months Bristol Myers Squibb's Zeposia (ozanimod) with a March 25thPDUFA date and Janssen's ponesimod with a potential decision by the end of 2020. Pre-launch assessment data captured in the current survey suggest that Zeposia uptake patterns will differ from those seen for Mayzent, with a greater opportunity within RRMS compared to active SPMS. However, as the third-to-market S1P receptor modulator, anticipated Zeposia trial rate within the first six months of availability is substantially lower than what Spherix measured at the same time pre-Mayzent launch.

Yet, pre-launch perception does not need to become post-launch reality. A Zeposia label with data on cortical grey matter and thalamic volume loss reduction and delayed cognitive worsening, combined with no first-dose observation requirement and no liver function abnormalities, could help Zeposia become the S1P receptor modulator of choice for the treatment of RRMS. Indeed, one-third of neurologists selected one of these four attributes as the greatest competitive advantage for a new S1P receptor modulator. Assuming an approval later this month and commercial availability soon after, Spherix will track the first 18 months of the Zeposia launch beginning in May, allowing for benchmarking to earlier launches of Vumerity, Mayzent, Mavenclad, and Ocrevus in the MS market.

About RealTime DynamixRealTime Dynamix: Multiple Sclerosis (US)is an independent service providing strategic guidance through rapid and comprehensive quarterly reports, which include market trending, launch tracking, and a fresh infusion of unique content with each wave. The 18th wave of research will publish in June 2020.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Virginia Schobel, Neurology Franchise HeadEmail:info@spherixglobalinsights.comwww.spherixglobalinsights.com

Reference:

1. Genzyme's Lemtrada and EMD Serono's Mavenclad, generally recommended for use after one or more previous failure, did not have the CIS indication added in their RMS label.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genentechs-ocrevus-offers-stiff-competition-to-the-new-high-efficacy-oral-therapies-novartis-mayzent-and-emd-seronos-mavenclad-while-biogens-vumerity-begins-to-chip-away-at-the-companys-own-tecfidera-301020893.html

SOURCE Spherix Global Insights

Excerpt from:
Genentech's Ocrevus Offers Stiff Competition to the New High-Efficacy Oral Therapies, Novartis' Mayzent and EMD Serono's Mavenclad, While Biogen's...

Patients with Parkinson disease (PD) tend to have an increase in iron content with reduced perfusion in the substantia nigra, as well as structural abnormalities and reduced flow in the left dural sinuses, according to study results published in Parkinsonism and Related Disorders.

Although limited data are available on the microvasculature of the brain in PD, several studies have reported that abnormal flow to the substantia nigra pars compacta could play a role in the pathogenesis of PD. The goal of the current study was to explore the vascular abnormalities, flow, and increases in midbrain iron content, a hallmark of the disease, in patients with PD.

The study cohort included 85 patients (45 women; mean age, 58.79.6 years) with PD from the neurology department of the First Affiliated Hospital of Zhengzhou University, Henan, China, and a similar number of age- and sex-matched control individuals (44 women; 60.29.9 years) from the province of Henan.

All participants were scanned with 3T MAGNETOM Prisma scanners, and the researchers assessed vascular abnormalities, using magnetic resonance venography; average cerebral blood flow, using 2-dimensional flow quantification; and substantia nigra iron content using susceptibility mapping. The patients with PD and healthy control individuals were divided into 4 vascular categories according to the presence or absence of dural sinuses and their flow characteristics.

The researchers reported that in patients with PD, there were abnormalities in flow, perfusion, and dural sinus structural characteristics. Venous structural and functional abnormalities in the 2 most severe categories were evident in 42% of patients with PD, whereas only 14% of the controls showed these abnormalities. Total arterial flow (normal range varies from 10 to 20 mL/s) was significantly lower for the PD group (10.91.8 mL/s) compared with for healthy control individuals (11.62.1 mL/s; P =.02).

Little flow on the left side was evident in 53% of the patients with PD compared with 14% of the healthy control individuals. Patients with PD also had higher heart rates (mean 7516 vs 679 beats per minute for the patients with PD and control individuals, respectively) and lower perfusion (489 vs 518 mL/100 g per minute, respectively). The lower perfusion correlated with increased iron content in the substantia nigra.

The study had several limitations, according to the researchers, including no data on local perfusion in the midbrain; limitations secondary to 2-dimensional, instead of 3-dimensional, flow analysis; and possible effect of various factors on venous shape and morphology.

These results suggest that abnormal flow could play a role in the etiology of PD, advancing our understanding of this debilitating disease, conclude the researchers.

Reference

Zhang C, Wu B, Wang X, et al. Vascular, flow and perfusion abnormalities in Parkinsons disease. Parkinsonism Relat Disord. 2020;73:8-13.

View original post here:
Abnormal Cerebral Blood Flow May Influence the Etiology of Parkinson Disease - Neurology Advisor

Tokyo Feb 1, 2020 (Thomson StreetEvents) -- Edited Transcript of Eisai Co Ltd earnings conference call or presentation Friday, January 31, 2020 at 7:30:00am GMT

Eisai Co., Ltd. - Senior VP & President of Neurology Business Group

Eisai Co., Ltd. - Executive VP, CFO & Chief IR Officer

Eisai Co., Ltd. - VP and Chief Medicine Creation Officer & Chief Discovery Officer of Oncology Business Group

Eisai Co., Ltd. - Senior VP & President of Oncology Business Group

Daiwa Securities Co. Ltd., Research Division - Research Analyst

Nomura Securities Co. Ltd., Research Division - Senior Analyst

Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., Research Division - Senior Analyst

Thank you very much for taking your time to attend the financial results presentation session by Eisai on the third quarter fiscal 2019.

Before we begin, there are some housekeeping announcements. Please make sure that you have the distributed materials in front of you. There should be a deck of slide that will be used in the presentation and flash report and related materials. If any of the document is missing, please raise your hand.

Then I would like to introduce the speakers today, Executive Vice President, CFO, Chief IR, Mr. Ryohei Yanagi; Senior Vice President and President of Neurology Business Group, Mr. Ivan Cheung; and Senior Vice President and President of Oncology Business Group, Mr. Terushige Iike.

Today's presentation will be made by Mr. Yanagi to cover the first part, which is financial part, and the latter part, operation part, will be presented by Mr. Cheung and Mr. Iike.

Ryohei Yanagi, Eisai Co., Ltd. - Executive VP, CFO & Chief IR Officer [2]

Now I would like to report it to you. On the part, covering the financials. Here is the Q3 9 months cumulative consolidated statement of income.

Revenue, top line, was JPY 486.1 billion, up 4% year-on-year. All global brands grew 44% from a year earlier. Growth driver, LENVIMA could reach the revenue of JPY 80.5 billion, increased by JPY 37.2 billion, 1.9x as much as last year, so almost doubled. And rapid growth of LENVIMA for a transfer of generic business, brought about the improvement of product mix, and cost ratio has improved or lowered to 26.2%.

As a result, gross profit was JPY 358.9 billion, up 10%, up from a year earlier. The double-digit growth was achieved, within the increased ratio of the gross profit. Within this increased ratio, the total cost increase ratio was controlled and financial discipline worked well, and OP grew about 30%.

And let me share with you the breakdown of expenses. R&D expenses were JPY 103 billion, which seems on the flat from a year earlier. But including partners reimbursement, actual R&D -- total R&D expenses were JPY 151.8 billion, 14% increase from year earlier. And this -- these expenses account for over 31% of revenue.

Among the top-tier Global 25 companies, we can say that we have been one of the most proactively investing company in R&D in the world. And SG&A expenses were JPY 188.4 billion, 12% increase and -- from a year earlier and SG&A expenses have account for 38.8% of revenue. Difference from a year earlier, the JPY 20 billion increase was mostly due to the payment to -- but due to the profit sharing related to LENVIMA. Therefore, given the robust growth in LENVIMA, a positive spending was made. Such cost of profit sharing with the Merck, excluding that impact, SG&A expenses were almost flat, and they accounting for 31% of revenue. And there is no much deviation from the median of global peer companies.

Operating profit was JPY 73.3 billion, up 30% from a year earlier. OP margin has exceeded a 15% mark.

During the third quarter, noteworthy things were the reversal of provisions on income taxes in the U.S., and there was increase in income taxes of the company following the repayment of trading capital from U.S. subs to the company to resolve the group's cash imbalance. Therefore, tax position improved significantly.

Bottom line profit for the period attributable to owners of the parent reached JPY 73.3 billion, 83% increase from a year earlier, a significant increase, and a 9 months cumulative reference value for ROE exceeded 15%, reaching global standard.

Looking at the balance sheet items. For this fiscal year, which we regard as a proactive investment year, and we are increasing the dividend by JPY 10 to JPY 160 per share for full year dividend. And the -- a little less than JPY 30 billion was expensed for capital investment in the past. But this fiscal year, we are doubling up to JPY 60 billion in CapEx, proactive investment is being made into ICT or ventures or a PP&E.

Therefore, net cash has slightly decreased, but net DER is minus 0.22. Therefore, net -- very significant net cash position is maintained, and the capital ratio is exceeding 61%. The debt free status is maintained. Therefore, we do not have any concerns on the financial strength. Therefore, we are achieving those proactive investment and dividend payments.

Next, here is a breakdown of revenue migration. Last year, 9 months cumulative revenue was JPY 467.3 billion. And given the growth of 4 global brands, Japan, China, Asia business is through the revenue and LENVIMA associated milestone payments was JPY 225 million last year, but it has reduced to JPY 150 million this year. But we are expecting to reduce significant milestone payment in the fourth quarter. Transfer of shares of Elmed Eisai and due to other factors in the business development related factors, revenue increased by JPY 18.8 billion year-on-year to reach JPY 486.1 billion.

Next, please.

On this slide, you can see the breakdown of operating profit migration and this waterfall chart. And last year, OP was recorded at the JPY 57.1 billion, in parallel to the movements in revenue due to growth 4 global brands, Japan, China, Asia, we could record the steady growth in OP. And as I said earlier, milestone payments related to LENVIMA were slightly decreased, but we expecting to receive significant milestones in the fourth quarter. Due to the proactive spending, the increase of the shared profit paid by Eisai to Merck related to LENVIMA was JPY 20 billion, and R&D expenses were almost flat. And inclusive of the impact by BD-related factors and -- OP increased by JPY 16.2 billion year-on-year to reach JPY 73.3 billion.

R&D expenses may have seemed to be almost flat from a year earlier, but inclusive of the reimbursement from partners in the amount of JPY 48.7 billion. Therefore, actual spending was JPY 151.8 billion. Therefore, a double-digit growth was observed in the R&D expenses.

Towards the future, we are making the proactive investment in R&D, while we are -- we have achieving the 30% significant increase in OP. And I think this is the benefit of the partnership model.

On this slide, we are providing you with a full year forecast for earnings. Revenue will be JPY 680 billion. Operating profit will be JPY 110 billion. These have remained unchanged from the last announcement. As I said earlier, due to the improvement in tax position, the lines from profit for the year below have been revised upward. And the profit targets set for 2020 have been already -- will be achieved year earlier.

And in FY 2006, the profit for the year is going to record -- put a record high profit, exceeding the record in 2006, and ROE will exceed 15%; and DOE, 7%; and ROE, 15%, which is set under EWAY 2025 for 2025 will be achieved.

As I said earlier, with strong balance sheet, DOE will be regarded as KPI, and the dividend per share will be maintained at this JPY 160. We do not have any concern about that. Through these, we are trying to maximize enterprise value. We have -- I have covered the financial section, and as the source of the profit and revenue, operations will be covered by a responsible persons of oncology -- neurology and oncology after me.

--------------------------------------------------------------------------------

Ivan Cheung, Eisai Co., Ltd. - Senior VP & President of Neurology Business Group [3]

--------------------------------------------------------------------------------

Today, I would like to cover neurology product development status for the third quarter.

First of all, I would like to talk about aducanumab and BAN2401, and I'd like to give you the update on the development for aducanumab. Currently, Biogen is actively engaging with the FDA as well as regulators in Europe and Japan. And In order to complete regulatory filing in the U.S. as soon as possible, we are working with Biogen in preparation, and the protocol has been already filed with FDA for aducanumab. And we are coordinating and cooperating with Biogen.

On the other hand, for BAN2401 through collaboration with ACTC, AD prevention study is being planned. This study was named AHEAD 3-45. In this study, its real clearance of protofibril in participants -- in clinically normal participants, we are planning to study and evaluate the prevention of progression of brain pathophysiology.

Phase III cohort will include cognitively normal participants with intermediate levels of amyloid as determined by amyloid PET scan. And the A45 cohort will include participants with little to no cognitive impairment who have elevated levels of amyloid in the brain. These 2 cohorts will be enrolled in 1 single study, in this Phase III study. And we have already signed a contract with ACTC and targeting amyloid how neurodegeneration or biomarker panels by ATN will be used as endpoints, and we plan to initiate this Phase III study in this year, 2020. And Phase III study, Clarity AD, which is currently ongoing, targeting patients with early AD, which is ongoing steadily, in Japan, the U.S., EU and Asia. And by this year, we plan to complete patient enrollment, final readout of primary endpoint is targeted in the first quarter in fiscal year 2022.

In addition to these studies, Phase II open-label extension study will be conducted on the same patient population of the Phase II Study 201, given the positive results of the Study 201, open-label extension study has been already started for evaluating long-term safety and efficacy.

Next, here is the BAN2401 Study 201-OLE, the baseline data was published in CTAD in December last year. After the completion of the treatment with BAN2401, brain amyloid reduction at the end of core persists after BAN2401 discontinuation for amyloid PET SUVr. This chart shows the changes after the average of 2 years of treatment in Study 201.

Emulated reduction was founded to be almost maintained for about to 2 years on the average after discontinuation of BAN2401, and a treatment difference for clinical outcomes at the end of core appears to be maintained following BAN2401 discontinuation.

Given this data, but just BAN2401's potential disease-modifying effects.

Next, about new insomnia treatment, DAYVIGO, is what I'd like to explain. DAYVIGO is in-house discovered and developed dual orexin receptor antagonist. Last year, in December, in the United States, it was approved for treatment of insomnia, and in Japan, in January, approval was obtained.

DAYVIGO exhibits both OX1R, OX2R orexin receptors, thereby, alleviate excessive awake condition. And especially, it is involved in -- it has stronger inhibition effect in orexin 2 receptor, which is involved in suppression of no REM sleep.

There are 2 Phase III studies, SUNRISE 2 and SUNRISE 1. And insomnia -- correction, sleep onset and sleep maintenance were demonstrated with statistical significance. And in SUNRISE 2, long-term efficacy and safety were observed.

Sleep well, wake well, be well, will be realized by DAYVIGO, and there is no rebound insomnia, and for chronic insomnia, long-term treatment is possible. For insomnia patients, we aim to contribute to such patients with sleep disorder by improving their symptoms.

In the United States, we plan to launch following scheduling by the U.S. DEA. And in Japan, we plan to launch in the first quarter of fiscal 2020. There are social issues caused by insomnia disorder. Approximately 30% of adults worldwide have symptoms of insomnia, and up to 10% are diagnosed as insomnia, approximately 10 million in U.S. and approximately 4.5 million in Japan are receiving treatment for insomnia.

Poor sleep is associated with a wide range of health consequences, including hypertension, accidental injury, diabetes, obesity, depression, heart attack, stroke and dementia.

Disease risks may be elevated by poor sleep. Due to difficulty falling asleep and staying asleep, patients may suffer from fatigue, difficulty concentrating and irritability, and productivity may decline as a result. DAYVIGO seeks to decrease negative impact on society caused by sleep disorder to fulfill patients' unmet needs.

Turning to Fycompa next. In this -- in the past quarter, we were able to make progress in value maximization for patients. In China, in December 2019, for adjunctive treatment of partial onset seizure, we were able to launch Fycompa. Fycompa was designated for Priority Review. And after submission within 12 months, we were able to obtain approval. In Japan, in January this year, approval was given for additional indications -- the following 3 additional indications: monotherapy for partial onset seizures, pediatric use in partial onset seizures, new formulation of fine granules at the same time. In EU pediatric use in partial onset seizures is under review and LGS Global 3 study is steadily ongoing.

As for IV formulation, in the United States and in Japan, we aim to submit in early fiscal 2020, and and in EU within fiscal 2020. So with Fycompa, we are expanding launch countries and receiving approvals of new indications and new formations. And this provides new treatment options to patients with epilepsy.

This is my last slide. In neurology area, this is the development pipeline. After October last year, we were able to launch 2 products and obtain 5 approvals and initiate 1 Phase I study. And our neurology portfolio is steadily growing.

As you can see, as a pharmaceutical company, we are addressing because of AD amyloid tau in neurodegeneration, all of ATN as the only company to do so. We are approaching ATN, and we have a pipeline of disease-modifying drug that approaches ATN. Regarding tau, we have E2814 new anti-tau antibody, and we were able to initiate Phase I study. In AD, there are differences with other tau related disease. There is highly toxic MTBR, which tend to be aggregated in the brain, and MTBR or microtubule binding region fragments are increasing with reduced this characteristic. And MTBR fragments are certainly causing tau degeneration propagation by accumulating in brain.

And unlike other anti-tau antibody, E2814 can target MTBR fragments and maybe able to exhibit a strong disease-modifying effect according to our understanding. The achievements in neurology area in the third quarter was presented in my presentation. Thank you.

--------------------------------------------------------------------------------

Terushige Iike, Eisai Co., Ltd. - Senior VP & President of Oncology Business Group [4]

--------------------------------------------------------------------------------

Next, I would like to report on our progress in oncology area. In the beginning, as my colleague, Mr. Yanagi mentioned, LENVIMA achieved JPY 80.5 billion sales cumulatively over 3 quarters. This is a growth of 86% over the previous year, same period, which is a strong growth.

Americas were boosted by HCC, and last September, approval was obtained for endometrial carcinoma, which is an indication for -- endometrial carcinoma, which exacerbated for systemic therapy and the LENVIMA was the first drug in the United States to receive indication for this. And it is expanding smoothly, and in China, in Japan as well, HCC-led our sales.

In HCC, tumor size may be large or tumor number maybe too many, and local therapy may not be suitable for such patients. LENVIMA can be given to shrink tumors. And then curative local therapy, including TACE may be applied, and this is called conversion therapy. Already in Japan, about 60 patients are undergoing this conversion therapy.

As for EMEA, Germany is showing the fastest growth. And in Russia, LENVIMA was listed in the national guideline and is also growing at the pace similar to Italy and France. For this fiscal year, LENVIMA sales is expected to exceed $1 billion.

This month in the Journal of Clinical Oncology, Phase I/II study results of combination between LENVIMA and KEYTRUDA were published. There are 6 types of cancer that were targeted for the study. As shown in this waterfall block, there is tumor a shrinkage observed, and safety profile is showing that the safety is manageable. In case of RCC, tumor shrinkage or overall response is 70% and duration of response is 20 months, and therefore, good results are obtained. And patients who die from cancer are most of the patients die from lung cancer, and NSCLC accounts for majority of the lung cancer, ORRs 33%, DOR was 11 months.

We do not (inaudible) based on previous therapy in these studies. Most of the patients who participated in the study may have received the immuno checkpoint the drug, including KEYTRUDA. Despite that, ORR and DOR as high as these were achieved. In multiple types of cancer, a combination of LENVIMA and KEYTRUDA, cancer was -- cancer back bone therapy, that is our belief, and we are carrying out studies for submission. Pivotal studies are underway. This is the development of combination therapy with KEYTRUDA, but in neck cancer first-line study included 12 studies have been initiated. One study that is remaining, which is second line for head and neck cancer, is under preparation. And 2 days ago, clinical trial disclosure was made so we were not able to include that in this slide. There is one more trial that is added, that is for HCC in combination with TACE. This TACE is transcatheter chemoarterial embolization (sic)

[transarterial chemoembolization] and in combination with LENVIMA, KEYTRUDA, TACE, the study will be carried out. And this was not included initially in our contract with Merck. But in HCC, there is an outstanding usefulness observed in combination therapy. And last year, after consultation with the Merck, the 2 parties decided to start this study. And 6 types of cancers are covered by LEAP-005 in basket-study style, triple-negative breast cancer, gastric cancer, included 6 sites of cancer are included. The ASCO, the other day -- Japanese doctors announced the results of 69% of ORR for gastric cancer for combination therapy with KEYTRUDA, and LEAP-005, in which Japanese doctors announced investor-initiated trial results, and we will be getting results from LEAP-005 as well.

So about next steps, we would like to consult with our partner Merck.

Turning to China, which is our important region. For HCC indication, JPY 10.7 billion revenue was accumulated in Q3 fiscal 2019, exceeding revenue in Japan and EMEA. Through collaboration with MSD, we are expanding contribution to patients, mainly in city areas by increasing commercial resources and by increasing coverage, and in regions and to small and medium-sized hospitals, through utilization of e-marketing, we would like to expand patient access.

As for thyroid cancer -- differentiated thyroid cancer, global Phase III is already completed. And based on the results, submission was accepted by the authority. As for the thyroid cancer incident in China, approximately 190,000 new cases are diagnosed. And that number in Japan is 20,000. So in China, it is almost a tenfold. And there is a strong unmet medical need. And we are making utmost efforts in our response to the review process by the authority.

For Halaven, this is Eisai in-house developed compound. And in January the 12, we had a launch event. After launch in December 2019, approximately 370,000 new cases of breast cancer are diagnosed in Japan. So this is about 5x that in Japan. And a Fareston hormonal therapy for breast cancer has been launched in China since 9 years ago. Using that base, we would like to build for Halaven to Chinese patients.

Next, E7090 fibroblast growth factor receptor inhibitor. FGFR 1, 2, 3 selective inhibitor is E7090. At Tsukuba Research Laboratories, using LENVIMA discovery know-how and compound library, E7090 was discovered and developed. Phase I expansion part result was published at ASCO-GI the other day. FGFR2 mutation biliary tract cancer or gastric patients -- gastric cancer patients are included in this expansion plan. And those was 140-milligram in the earlier dose escalation part. Higher dose was considered, however, biomarkers suggest that sufficient efficacy is obtained at 140 milligram and that is why this dose was selected. Red bars are biliary tract cancer. Out of 6 of 5 are tumor shrinkage and 1 had stable disease, so strong efficacy was observed.

Blue is gastric cancer. Perhaps other than FGFR2, other factors may be contributing to proliferation of cancer. There seems to be cancer heterogeneity in gastric cancer, more so than in biliary tract cancer.

FGFR2 fusion, biliary retract cancer, on this, we received SAKIGAKE designation from MHLW last year. In consultation with the authority, we have decided to conduct a joint Phase II study, jointly between Japan and China, and this has already been started. In the 3 months, we were able to launch one product and one submission and initiation of one Phase III, one Phase II and one Phase I studies in oncology, E7766 STING agonist.

This is a Phase I study. Two Phase I studies will be run in parallel, and one is injection in the tumor and the other is injection in bladder for bladder cancer patients. And breast cancer in HCC pipelines are also making progress for early development products, and combination with KEYTRUDA in LEAP study series, we expect results of one after another from LEAP studies this year and next year for these types of cancer so that they can serve -- so that the therapy can serve as a backbone therapy, we would like to work together with Merck. That concludes the oncology presentation part.

Then I would like to summarize at the end. Today, the three speakers have presented. Eisai's operations and financials are currently very robust and making strong advances. EWAY 2025 vision is medical societal innovator. For example, as explained today, next-generation AD treatment is medical innovation. And that is based on ecosystem, which is quite inclusive, and this can turn into a massive social innovation, and we are making steady progress in implementing such a business model. And as a result, EWAY 2025, at the time of 2025, ROE of 15% level should be achieved in stable fashion and that probability of success is being enhanced. Furthermore, over extremely long term, beyond 2025 -- even beyond 2025, there should be contribution to enterprise value due to a rich pipeline filled with next-generation product candidates and progress is made.

At Eisai, long-term sustainable growth of enterprise value is pursued. And amongst stakeholders, we hope that we continue to receive your support.

With that, I would like to conclude. Thank you very much.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Unidentified Company Representative, [1]

--------------------------------------------------------------------------------

Next, we would like to open the floor for questions. First, we would like to entertain questions in this room before receiving questions from participants over the phone. If you have questions, please do use the microphone, and please give us your name and affiliation before your question. If you have questions, please raise your hand.

--------------------------------------------------------------------------------

Motoya Kohtani, Nomura Securities Co. Ltd., Research Division - Senior Analyst [2]

--------------------------------------------------------------------------------

My name is Kohtani. I am from Nomura Securities. I have three questions about oncology. First, ASCO-GI, as you said that IIS EPOCH 1706 and 29 patients included. Therefore, 69% was the response rate and that the sample size were very small, but although -- but it was not a coincidence. And with the monotherapy KEYTRUDA, the response was 15%. And then with the chemotherapy -- and then only 45% -- with the chemotherapy, 40%. And with the chemotherapy 45% -- 5% was the response rate. Please let me know.

LENVIMA monotherapy in gastric cancer, what kind of data was published? Are there any such data and VEGF and PD-L1 antibodies? And do you think that there has been a powerful synergy with PD-L1 antibodies like the KEYTRUDA?

Probably, it will be difficult to file solely based on this study data. But I think you mentioned earlier, this is with Merck, LEAP or we did include it in the basket trial being conducted with Merck is adding such a study. And then how this addition will -- may have an impact on your clinical development?

--------------------------------------------------------------------------------

Unidentified Company Representative, [3]

--------------------------------------------------------------------------------

Thank you for your question. Dr. Owa, who is in charge of science of oncology. Dr. Owa is going to respond to questions.

--------------------------------------------------------------------------------

Takashi Owa, Eisai Co., Ltd. - VP and Chief Medicine Creation Officer & Chief Discovery Officer of Oncology Business Group [4]

--------------------------------------------------------------------------------

Thank you very much, Mr. Kohtani. Regarding your first point, LENVIMA monotherapy data for gastric cancer. What kind of data do we have for LENVIMA monotherapy , for example, with 20 or 30 patients with gastric cancer, we do not have any data for monotherapy. But so far, Phase I study were conducted for LENVIMA and that there were gastric cancer patients involved. And for -- even for monotherapy, there were partial response. That data is available, but there is nothing taken from this data because the sample size was not large enough.

--------------------------------------------------------------------------------

Motoya Kohtani, Nomura Securities Co. Ltd., Research Division - Senior Analyst [5]

--------------------------------------------------------------------------------

And so how should we interpret this data?

--------------------------------------------------------------------------------

Original post:
Edited Transcript of 4523.T earnings conference call or presentation 31-Jan-20 7:30am GMT - Yahoo Finance

People with neurological conditions like Parkinsons disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS, also known as Lou Gehrigs disease), Huntingtons disease, and dementia are at higher risk for suicide, a study published in February 2020 in the Journal of the American Medical Association has found.

According to the authors, from the Danish Research Institute for Suicide Prevention (DRISP) in Copenhagen, the higher rates of suicide among those with these brain disorders are likely the result of stress and feelings of hopelessness when they learn their diagnosis and prognosis. Although the symptoms of most of these conditions can be managed with drug treatments and other approaches, none can be cured at least not yet.

In addition, many of these disorders lead to significant disability, which may impact the quality of life of those who are diagnosed as well as their families and friends.

Distress at the time of diagnosis plays a role, for instance, for people with dementia, explains study coauthor Annette Erlangsen, PhD, who heads the research program at DRISP. For severe disorders, such as Huntingtons and ALS, the risk of suicide might be related to the course of the disorder.

Some of these disorders, perhaps as a result, are also linked with a higher risk of mood disorders like depression and anxiety, which may lead to thoughts of suicide, she adds.

To assess the risk of suicide among people with certain neurological disorders, Dr. Erlangsen and her colleagues reviewed the health records of more than 7.3 million people in Denmark from 1980 through 2016. All of the people included in the analysis were 15 years of age or older as of 1980, and approximately 1.25 million of them had received medical treatment for a head injury, stroke, epilepsy, polyneuropathy, diseases of myoneural junction (in which signals from nerves to muscles are disrupted, leading to muscle weakness and fatigue), Parkinsons, MS, central nervous system infections, meningitis, encephalitis, ALS, Huntingtons, dementia, intellectual disability, and other brain-related conditions during the study period.

Ultimately, more than 35,000 of those included in the analysis died by suicide, and nearly 15 percent of those who died by suicide had been diagnosed with a neurological disorder. Overall, Erlangsens team found that those with neurological disorders are almost twice as likely to take their own lives as those who hadnt been diagnosed with these conditions.

Risk of suicide among those with ALS was almost 5 times higher than that of the general population, while the suicide risk for those with Huntingtons, MS, and epilepsy was roughly twice as high.

The researchers also found that the risk of suicide rose as the number of hospital visits rose.

RELATED: What Your Doctor Wont Tell You About Epilepsy: It Can Kill You

Based on their findings, the authors suggest that caregivers friends and loved ones as well as healthcare professionals closely monitor those with these conditions for depression and anxiety, emotional distress, and suicidal thoughts.

Its important to emphasize that suicide is a rare event in general and also among people with neurological disorders, Erlangsen says. However, she adds, Its surely important to be aware of ones mental well-being especially when diagnosed with a chronic disorder. Luckily, its few who develop depressive symptoms, but if one does, then it is important to speak to a healthcare professional and assess whether further initiatives are needed.

More here:
Study Finds Suicide Rate Higher Among Those With Neurological Disorders - Everyday Health